Key Takeaways
- • Graphite Capital has agreed to sell Beacon, its life sciences data and workflow platform, to Corten Capital, with the transaction expected to close by end of June 2026 and deliver a 4x cash return on Graphite's original 2019 investment in Hanson Wade.
- • Beacon serves over 300 customers including a significant portion of the world's largest pharmaceutical groups, providing decision-support tools and analytics for research and development investment guidance across the life sciences sector.
- • Under Graphite's ownership, Beacon expanded from three to sixteen datasets, with enhanced coverage in therapeutic areas including oncology and neuroscience, plus integration of AI-assisted workflows and API functionality to embed analytics deeper into customer workflows.
- • Graphite is retaining control of the broader Hanson Wade business for continued growth initiatives, with Beacon transitioning to independent status as a standalone information services provider post-acquisition.
- • Beacon's recurring revenues increased significantly during Graphite's ownership period, driven by dataset expansion, commercial capability development, and product enhancements reflecting market demand for embedded analytics in pharmaceutical drug development decision-making.
Summary
Graphite Capital has completed an agreement to divest Beacon, a life sciences data and workflow platform, to Corten Capital in a transaction expected to deliver a 4x cash return on Graphite's initial 2019 investment in parent company Hanson Wade. The deal, anticipated to close by end of June 2026, represents a substantial exit from a platform-building initiative within the pharmaceutical and biotech analytics sector.
Beacon provides decision-support tools used by senior scientists across global life sciences organizations to guide research and development investment allocation. The platform serves more than 300 customers, including a material concentration among the world's largest pharmaceutical groups, positioning it as a critical node in drug development decision infrastructure. Following the acquisition completion, Beacon will operate as an independent information services provider, while Graphite retains ownership of the broader Hanson Wade business for additional growth initiatives.
During Graphite's seven-year ownership period, Beacon underwent substantial product and commercial expansion. The platform's dataset coverage grew from three to sixteen distinct datasets, with particular expansion in therapeutic areas such as oncology and neuroscience. Product enhancements included rollout of API functionality and deeper integration of data services into customer workflows, reflecting end-market demand for embedded analytics capabilities in pharmaceutical R&D decision-making. Recurring revenues expanded significantly during this period, supported by these product developments and expanded commercial capabilities. The platform also integrated AI-assisted workflows under scientific oversight, addressing industry demand for advanced analytical capabilities while maintaining data quality standards and scientific rigor.
Management attributed the platform's scaling success to Graphite's operational support in accelerating global expansion and product development, while emphasizing continued investment in data quality and scientific expertise as foundational to the platform's competitive positioning. The transaction underscores sustained institutional investor appetite for specialized data and analytics platforms serving regulated life sciences sectors, where embedded decision support tools command embedded positions within customer workflows.
Beacon provides decision-support tools used by senior scientists across global life sciences organizations to guide research and development investment allocation. The platform serves more than 300 customers, including a material concentration among the world's largest pharmaceutical groups, positioning it as a critical node in drug development decision infrastructure. Following the acquisition completion, Beacon will operate as an independent information services provider, while Graphite retains ownership of the broader Hanson Wade business for additional growth initiatives.
During Graphite's seven-year ownership period, Beacon underwent substantial product and commercial expansion. The platform's dataset coverage grew from three to sixteen distinct datasets, with particular expansion in therapeutic areas such as oncology and neuroscience. Product enhancements included rollout of API functionality and deeper integration of data services into customer workflows, reflecting end-market demand for embedded analytics capabilities in pharmaceutical R&D decision-making. Recurring revenues expanded significantly during this period, supported by these product developments and expanded commercial capabilities. The platform also integrated AI-assisted workflows under scientific oversight, addressing industry demand for advanced analytical capabilities while maintaining data quality standards and scientific rigor.
Management attributed the platform's scaling success to Graphite's operational support in accelerating global expansion and product development, while emphasizing continued investment in data quality and scientific expertise as foundational to the platform's competitive positioning. The transaction underscores sustained institutional investor appetite for specialized data and analytics platforms serving regulated life sciences sectors, where embedded decision support tools command embedded positions within customer workflows.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.